Global Irritable Bowel Syndrome Drugs Market Trends, Forecast Report 2025-2037
Irritable Bowel Syndrome Drugs Market size is poised to rise from USD 4.14 billion to USD 11.53 billion, exhibiting a CAGR of more than 8.7% during the forecast timeline, from 2025 through 2037. In the year 2025, the industry size of irritable bowel syndrome drugs is estimated at USD 4.43 billion.
The market growth is driven by increasing number of elderly people who are prone to different types of gastrointestinal diseases. Further, growing prevalence of gastrointestinal diseases amongst other population group, an increase in the consumption of unhealthy foods, and rising stress levels among people across the globe is expected to boost the market demand.
In addition, the market revenue is propelled by rise in over-the-counter drug availability, soaring investments, and collaboration between major key players to discover effective treatments for IBS. For instance, on June 9, 2022, the biopharmaceutical company Ferring B.V. announced a strategic partnership with the innovation-focused global biopharma company I-MAB Biopharma Co., Ltd. to advance the development of olamkicept, a selective interleukin-6 (IL-6) trans-signaling inhibitor for inflammatory bowel disease (IBD) and associated inflammatory conditions. Additionally, the growing number of awareness campaigns on the management of irritable bowel syndrome is predicted to present the potential for market expansion.
Irritable Bowel Syndrome Drugs Sector: Growth Drivers and Challenges
Growth Drivers
- Growing Prevalence of Diarrhea in Children – On account of the increasing prevalence of gastrointestinal disorders in children, including diarrhea, constipation, and bowel incontinence, the market is expected to expand more in the upcoming years. Diarrhea is listed as the second most typical cause of death in children under the age of five by the World Health Organization. Each year, diarrhea kills about 500 000 children under the age of five. Around 2 billion children worldwide have diarrheal sickness every year.
- Rising Geriatric Population – Elderly population is more prone to bowel incontinence and the rising number of elderly populations across the globe is estimated to drive market growth. The percentage of individuals over 60 in the world will nearly double from 12 to 22% between 2015 and 2050. In 2020, there were more people over the age of 60 than children under five and by 2050, it is predicted that 80% of the world's old people will live in low- and middle-income countries.
- Increasing Health Spending – According to the most recent expenditure data, global health spending has grown over the past 20 years, doubling in real terms to reach USD 8.5 trillion in 2019 and 9.8% of GDP, up from 8.5 percent in 2000. It is predicted that this boom would continue over the forecast period.
- Growing Incidences of Spinal Cord Injuries – It is expected that patients with chronic illnesses and disabilities, including spinal cord injuries, experience bowel incontinence more severely, which is anticipated to drive the market growth. It was discovered that between 300,000 and 500,000 people worldwide experience spinal cord injuries every year.
- Rising Cases of Hemorrhoids – Hemorrhoids can also be referred to as piles. Inflamed veins in the lower rectum and anus are hemorrhoids. Bowel incontinence can result from this swelling, thereby raising the need for hemorrhoids drugs, which is anticipated to drive the market growth. At least 50% of Americans over the age of 50 who have hemorrhoids experience obvious symptoms.
Challenges
- Side effects of IBS drugs - The increasing concern amongst individuals for the side effects associated with the consumption of IBS drugs is one of the major factors predicted to slow down the market growth. For instance, pancreatitis, a serious and more common pancreatic inflammation, can arise from the dual mu-opioid nicotinic receptor eluxadoline, which is employed to address digestive problems with incontinence in some people.
- Low awareness among people in low and middle-income countries for these drugs
- Lack of medical reimbursement policies for treatment of IBS
Irritable Bowel Syndrome Drugs Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
8.7% |
|
Base Year Market Size (2024) |
USD 4.14 billion |
|
Forecast Year Market Size (2037) |
USD 11.53 billion |
|
Regional Scope |
|
Irritable Bowel Syndrome Drugs Segmentation
Type {IBS with Diarrhea (IBS-D), IBS with Constipation (IBS-C), Mixed IBS (IBS-M)}
The IBS with diarrhea (IBS-D) segment is predicted to dominate market share over the projected time frame. The segment growth can be attributed to increasing prevalence of diarrhea among all age groups and the rising adoption of unhealthy lifestyles including the consumption of fast food and alcohol. For instance, diarrheal illnesses are believed to be responsible for 300 annual pediatric fatalities and 167,000 hospitalizations in the US.
Our in-depth analysis of the global irritable bowel syndrome drugs market includes the following segments:
|
By Type |
|
|
By Product |
|
|
By End User |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportIrritable Bowel Syndrome Drugs Industry - Regional Synopsis
The North American irritable bowel syndrome drugs market is set to dominate majority revenue share by the end of 2037. The market growth can be attributed to the increasing frequency of fecal incontinence and the availability of efficient treatment options in the region. For instance, 50 to 70 patients out of every 100 nursing home residents and 18 to 33 patients out of every 100 hospitalized patients, respectively, suffer from fecal incontinence. Fecal incontinence affects 7 to 15 persons out of every 100 who are not patients or residents of nursing homes or hospitals. In addition, the region's supportive health policies and expanding healthcare industry are anticipated to boost the market expansion.
Companies Dominating the Irritable Bowel Syndrome Drugs Landscape
- Abbott Services
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Ardelyx, Inc.
- Astellas Pharma Inc.
- AstraZeneca
- GlaxoSmithKline Plc
- Johnson & Johnson Services, Inc.
- Novartis AG
- Ironwood Pharmaceuticals, Inc.
- Synergy Pharma Consultancy Private Limited
- Synthetic Biologics, Inc
In the News
-
IBSRELA the first and only NHE3 inhibitor for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults, has been made available by the biopharmaceutical company Ardelyx. The first Ardelyx product to receive approval from the US Food and Drug Administration is IBSRELA.
-
Indegene a provider of technology-driven healthcare solutions, and metaMe Health, a maker of Regulora and a Prescription Digital Therapeutics (PDT) business, teamed up to offer Regulora as a remedy for irritable bowel syndrome-related stomach pain (IBS).
Author Credits: Radhika Pawar
- Report ID: 3040
- Published Date: Jan 28, 2025
- Report Format: PDF, PPT
